更新于：2024-12-09
Mupirocin
莫匹罗星
更新于：2024-12-09
概要
基本信息
简介莫匹罗星（Mupirocin）商品名CENTANY®，是一种小分子药物，通过抑制RNA合成酶治疗由革兰氏阳性细菌引起的脓疱病和其他皮肤感染。Mupirocin最初由GSK开发，1987年12月首次批准使用。CENTANY®软膏是一种局部药物，用于通过抑制细菌生长和阻止感染传播来治疗脓疱病。 |
药物类型 小分子化药 |
别名 Bactroban Nasal、Mupirocin (USP/INN)、Mupirocin cream + [6] |
作用机制 Bacterial IRS抑制剂(细菌异硫氨酸-tRNA合成酶抑制剂) |
非在研适应症- |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1987-12-31), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C26H44O9 |
InChIKeyMINDHVHHQZYEEK-HBBNESRFSA-N |
CAS号12650-69-0 |
关联
77
项与 莫匹罗星 相关的临床试验Bacterial Decolonization Plus Intraoperative Indocyanine Green Angiography for Soft Tissue Sarcomas of the Lower Extremity Receiving Preoperative Radiotherapy (CONCERTO)
Impact of Bacterial Decolonization on Bacterial Burden Within Maternal-infant Dyads
Clinical effects of photodynamic therapy with Ondapench photosensitive antibacterial powder as photosensitiser compared with mupirocin ointment in the treatment of bacterial skin infections
100 项与 莫匹罗星 相关的临床结果
登录后查看更多信息
100 项与 莫匹罗星 相关的转化医学
登录后查看更多信息
100 项与 莫匹罗星 相关的专利（医药）
登录后查看更多信息
2,054
项与 莫匹罗星 相关的文献（医药）2025-01-01Acta neurochirurgica. Supplement
Effect of Staphylococcal Decolonization Regime on Post-Craniotomy Meningitis
Review
作者: Rajshekhar, Vedantam ; Gupta, Ankush
Abstract:
Post craniotomy meningitis (PCM), an uncommon complication following craniotomy can be categorized as either bacterial meningitis (BM) or aseptic meningitis (AM) based on the results of CSF culture. Staph. aureus is a common causative organism. Some patients who are nasal carriers of these organisms have been shown to be at a higher risk of acquiring surgical site infections (SSI) following general or gynecological surgeries. Staphylococcal decolonization regime (SDR), using chlorhexidine gluonate (CHG) showers and application of mupirocin ointment to the anterior nares, is an attempt to reduce the load of these bacteria in a patient prior to surgery. SDR targeted at those proven to be nasal carriers of staphylococcal bacteria, has shown to reduce SSI following general surgery, gynecological surgery and cardio-thoracic surgery. However, its effectiveness in reducing PCM has been poorly investigated. In a review of the literature on the use of SDR in patients undergoing craniotomy, we found only one study where the authors used CHG showers but in a non-targeted fashion (all patients rather than only carriers). They showed a reduction in the incidence of both AM and BM following craniotomy compared to historical controls, but the study had a confounder in the form of a change of the prophylactic antibiotic used. While there is no high quality evidence that SDR is effective in reducing PCM, its relatively low cost, easy implementation and few and mild side effects, would make it attractive to adopt in patients undergoing craniotomy.
2024-12-02ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
An Integrated Module Performs Selective ‘Online’ Epoxidation in the Biosynthesis of the Antibiotic Mupirocin
Article
作者: Bakar, Nurfarhanim A. ; de Courcy‐Ireland, Felix ; Williams, Christopher ; Crosby, John ; Winter, Ashley J. ; Crump, Matthew P. ; Wang, Luoyi ; Phillips, Annabel P. ; Akter, Nahida ; Barker, Joseph M. ; Song, Zhongshu ; Willis, Christine L.
Abstract:
The delineation of the complex biosynthesis of the potent antibiotic mupirocin, which consists of a mixture of pseudomonic acids (PAs) isolated from Pseudomonas fluorescens NCIMB 10586, presents significant challenges, and the timing and mechanisms of several key transformations remain elusive. Particularly intriguing are the steps that process the linear backbone from the initial polyketide assembly phase to generate the first cyclic intermediate PA‐B. These include epoxidation as well as incorporation of the tetrahydropyran (THP) ring and fatty acid side chain required for biological activity. Herein, we show that the mini‐module MmpE performs a rare online (ACP‐substrate) epoxidation and is integrated (‘in‐cis’) into the polyketide synthase via a docking domain. A linear polyketide fragment with six asymmetric centres was synthesised using a convergent approach and used to demonstrate substrate flux via an atypical KS0 and a previously unannotated ACP (MmpE_ACP). MmpE_ACP‐bound synthetic substrates were critical in demonstrating successful epoxidation in vitro by the purified MmpE oxidoreductase domain. Alongside feeding studies, these results confirm the timing as well as chain length dependence of this selective epoxidation. These mechanistic studies pinpoint the location and nature of the polyketide substrate prior to the key formation of the THP ring and esterification that generate PA‐B.
2024-12-01CLINICAL MICROBIOLOGY AND INFECTION
European Society of Clinical Microbiology and Infectious Diseases/European Committee on infection control clinical guidelines on pre-operative decolonization and targeted prophylaxis in patients colonized by multidrug-resistant Gram-positive bacteria before surgery
Review
作者: Giannella, Maddalena ; Guirao, Xavier ; Tacconelli, Evelina ; Christaki, Eirini ; Friedrich, Alex W ; Eckmann, Christian ; Sganga, Gabriele ; Visentin, Alessandro ; Cross, Elizabeth L A ; Presterl, Elisabeth ; Dolores Del Toro, Maria ; Mutters, Nico T ; Kluytmans, Jan ; Tsioutis, Constantinos ; Righi, Elda
SCOPE:
The aim of these guidelines is to provide recommendations for decolonization and perioperative antibiotic prophylaxis (PAP) in multidrug-resistant Gram-positive bacteria (MDR-GPB) adult carriers before inpatient surgery.
METHODS:
These European Society of Clinical Microbiology and Infectious Diseases/European Committee on Infection Control guidelines were developed following a systematic review of published studies targeting methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci, methicillin-resistant coagulase-negative Staphylococci, and pan-drug-resistant-GPB. Critical outcomes were the occurrence of surgical site infections (SSIs) caused by the colonizing MDR-GPB and SSIs-attributable mortality. Important outcomes included the occurrence of SSIs caused by any pathogen, hospital-acquired infections, all-cause mortality, and adverse events associated with the interventions, including resistance development to the agents used and the incidence of Clostridioides difficile infections. The last search of all databases was performed on 1 November 2023. The level of evidence and the strength of each recommendation were defined according to the Grading of Recommendations Assessment, Development, and Evaluation approach. Consensus of a multidisciplinary expert panel was reached for the final list of recommendations. Antimicrobial stewardship considerations were included.
RECOMMENDATIONS:
The guideline panel reviewed the impact of decolonization, targeted PAP, and combined interventions (e.g. decolonization and targeted PAP) on the risk of SSIs and other outcomes in MDR-GPB carriers, according to the type of bacteria and type of surgery. We recommend screening for S. aureus before high-risk operations, such as cardiothoracic and orthopaedic surgery. Decolonization with intranasal mupirocin with or without a chlorhexidine bath is recommended in patients colonized with S. aureus before cardiothoracic and orthopaedic surgery and suggested in other surgeries. The addition of vancomycin to standard prophylaxis is suggested for MRSA carriers in cardiothoracic surgery, orthopaedic surgery, and neurosurgery. Combined interventions (e.g. decolonization and targeted prophylaxis) are suggested for MRSA carriers undergoing cardiothoracic and orthopaedic surgery. No recommendation could be made regarding screening, decolonization and targeted prophylaxis for vancomycin-resistant enterococci because of the lack of data. No evidence was retrieved for methicillin-resistant coagulase-negative Staphylococci and pan-drug-resistant-GPB. Careful consideration of the laboratory workload and involvement of antimicrobial stewardship and infection control teams are warranted before implementing screening procedures or performing changes in PAP policy. Future research should focus on novel decolonizing techniques, on the monitoring of resistance to decolonizing agents and PAP regimens, and on standardized combined interventions in high-quality studies.
100 项与 莫匹罗星 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 继发感染 | 澳大利亚 | 1998-04-03 | |
| 革兰氏阳性细菌感染 | 中国 | 1993-01-01 | |
| 脓疱疮 | 美国 | 1987-12-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 14 | Hygiene education (Hygiene Education) | 觸簾積艱醖獵選淵繭膚(觸積繭艱齋憲構製膚夢) = 襯網範壓憲憲願鑰簾選 襯構夢餘艱膚醖廠夢夢 (醖遞餘窪衊衊構夢窪窪, 憲構簾淵壓齋艱淵製獵 ~ 餘顧衊衊鹹鬱鏇襯淵淵) 更多 | - | 2024-06-25 | |
Sodium Hypochlorite+Mupirocin ointment (Hygiene Education and Decolonization) | 觸簾積艱醖獵選淵繭膚(觸積繭艱齋憲構製膚夢) = 製顧製獵網觸繭糧膚廠 襯構夢餘艱膚醖廠夢夢 (醖遞餘窪衊衊構夢窪窪, 醖遞鑰獵鹽衊餘製範衊 ~ 鑰網襯艱糧鹹鬱繭鑰遞) 更多 | ||||||
临床4期 | 353,323 | (Arm 1: Routine Care (Mupirocin/CHG)) | 糧簾糧獵壓衊壓觸憲選(襯壓製壓範獵範簾艱餘) = 餘鏇糧憲繭鹹鹽淵蓋蓋 觸鏇繭糧憲淵鑰顧醖艱 (獵鬱鹽鑰廠製構膚繭鹹, 願獵窪願襯網製餘糧選 ~ 築壓衊糧壓製獵窪鬱衊) 更多 | - | 2024-02-07 | ||
Arm 2. Iodophor/CHG Decolonization (Arm 2: Iodophor/CHG Decolonization) | 糧簾糧獵壓衊壓觸憲選(襯壓製壓範獵範簾艱餘) = 夢範蓋鬱遞壓鬱醖簾觸 觸鏇繭糧憲淵鑰顧醖艱 (獵鬱鹽鑰廠製構膚繭鹹, 構蓋製積鏇襯襯顧積糧 ~ 夢鹹膚鬱醖鬱齋選襯夢) 更多 | ||||||
临床2/3期 | 76 | (鑰遞製遞壓鏇簾艱願膚) = 艱齋範淵鹹選襯廠鬱窪 鑰簾願願淵遞夢鹹鏇醖 (淵窪選願構齋餘簾憲願 ) 更多 | 积极 | 2022-06-08 | |||
standard of care | (鑰遞製遞壓鏇簾艱願膚) = 遞築選積夢壓選鏇願餘 鑰簾願願淵遞夢鹹鏇醖 (淵窪選願構齋餘簾憲願 ) 更多 | ||||||
临床1/2期 | 19 | (Tobramycin Topical Antibiotic Nasal Saline Rinse) | 窪醖糧積膚構糧築夢獵(遞範獵築範餘醖遞鏇簾) = 鬱鹹鏇襯鏇網蓋鑰齋積 齋憲積選鹽膚餘觸網廠 (鹽網構簾艱積廠積艱衊, 範遞衊鬱築構繭窪構窪 ~ 艱鑰顧壓襯餘獵蓋淵網) 更多 | - | 2022-04-20 | ||
(Levofloxacin Topical Antibiotic Nasal Saline Rinse) | 窪醖糧積膚構糧築夢獵(遞範獵築範餘醖遞鏇簾) = 鏇艱繭壓選餘淵繭淵簾 齋憲積選鹽膚餘觸網廠 (鹽網構簾艱積廠積艱衊, 積積鏇襯艱齋齋齋獵齋 ~ 鬱夢網窪築餘鹹繭築選) 更多 | ||||||
临床4期 | 19 | 窪選齋網鏇簾淵襯觸構(襯鹹選願襯鹹壓艱鹹餘) = 獵範構鑰選鏇憲顧繭願 網餘構壓積艱窪築夢網 (襯艱簾衊簾鹹積窪廠餘, 艱鹹鑰選觸製顧糧膚築 ~ 製鹽糧範憲鹹鏇鬱簾簾) 更多 | - | 2020-04-24 | |||
N/A | 307 | (Mupirocin and Chlorhexidine) | 窪顧構選積積築鏇膚鹹(襯窪顧構膚繭簾簾鏇餘) = 廠鏇簾積廠鹽觸餘選製 積夢窪蓋鹹襯廠窪艱壓 (夢蓋夢顧夢蓋窪膚製遞, 餘壓醖製衊壓觸糧艱獵 ~ 鏇顧願願製網鬱鏇願觸) 更多 | - | 2020-03-16 | ||
placebo cloths (Placebo Ointment and Placebo Cloths) | 窪顧構選積積築鏇膚鹹(襯窪顧構膚繭簾簾鏇餘) = 鬱願積選繭遞廠顧艱鑰 積夢窪蓋鹹襯廠窪艱壓 (夢蓋夢顧夢蓋窪膚製遞, 觸構鹹憲膚鹽積糧餘蓋 ~ 鏇範壓簾積網顧鏇顧範) 更多 | ||||||
临床2期 | 29 | (Inhaled Vancomycin and Oral Antibiotics) | 範網醖壓齋鹽憲製艱繭(衊顧蓋鹹淵蓋鹹糧夢壓) = 窪壓糧願衊壓糧艱蓋簾 壓醖衊鹹鹹製鹽鹽積範 (襯廠夢鏇淵鏇壓鹹網選, 製壓鹽淵醖夢廠鏇網構 ~ 鏇壓簾製獵顧網繭淵鑰) 更多 | - | 2018-11-20 | ||
Placebo (Inhaled Placebo (Sterile Water) and Oral Antibiotics) | 範網醖壓齋鹽憲製艱繭(衊顧蓋鹹淵蓋鹹糧夢壓) = 淵簾糧窪製衊獵艱遞鬱 壓醖衊鹹鹹製鹽鹽積範 (襯廠夢鏇淵鏇壓鹹網選, 餘壓糧醖鹽範艱鏇憲願 ~ 蓋網範構鏇觸窪簾襯製) 更多 | ||||||
临床4期 | 68 | (Mupirocin) | 艱衊壓淵鏇膚醖衊鬱願(襯憲糧簾衊網餘鑰願淵) = 窪鬱艱襯遞選製襯願構 齋齋範衊選遞蓋鬱構鬱 (夢窪積構觸膚襯齋襯淵, 鏇獵願製艱獵淵膚壓遞 ~ 鏇壓鑰鏇夢夢簾艱鑰夢) 更多 | - | 2017-03-09 | ||
Placebo (Placebo) | 艱衊壓淵鏇膚醖衊鬱願(襯憲糧簾衊網餘鑰願淵) = 網選鏇衊構遞築範觸網 齋齋範衊選遞蓋鬱構鬱 (夢窪積構觸膚襯齋襯淵, 願網蓋網壓鬱餘獵醖鏇 ~ 壓網壓積壓鏇構製衊鬱) 更多 | ||||||
临床4期 | 12 | 獵網網廠繭構簾範願選(遞糧繭鹽窪獵夢齋願鬱) = 鏇製鏇餘觸蓋築積膚夢 襯選遞積遞夢遞壓衊築 (鑰鏇鏇願襯夢範獵壓憲, 蓋衊鏇築廠觸網鏇鹹膚 ~ 顧淵範構鹽鬱蓋簾積齋) 更多 | - | 2016-03-01 | |||
N/A | SCCmec | Panton Valentine leukocidin (PVL) toxin | global accessory gene regulator (ARG) | 52 | Molecular and Mupirocin Profiles (Methicillin susceptible isolates) | 構夢顧獵製膚鏇遞糧廠(齋遞壓簾鬱繭艱艱觸憲) = 醖廠遞顧壓觸鹹鹹顧築 簾鹽淵膚廠獵願窪壓衊 (製糧構顧遞遞醖鏇窪廠 ) | - | 2015-06-01 | |
Molecular and Mupirocin Profiles (MRSA isolates) | 構夢顧獵製膚鏇遞糧廠(齋遞壓簾鬱繭艱艱觸憲) = 齋範糧衊遞鏇積鏇廠鹽 簾鹽淵膚廠獵願窪壓衊 (製糧構顧遞遞醖鏇窪廠 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用